To the Editor We read with interest the Original Investigation in a recent issue of JAMA Internal Medicine by Agar et al1 on the management of delirium in the palliative care setting. Delirium is one of the most common and disturbing syndromes at the end of life,2 and there are few well-designed studies to inform practice.3 Because data from geriatrics and other populations cannot be extrapolated to the palliative care setting, this important study1 provides unique insights into the role of haloperidol and risperidone compared with placebo; however, several issues regarding the study design complicate its interpretation.
Hui D, Valentine A, Bruera E. Neuroleptics for Delirium: More Research Is Needed. JAMA Intern Med. 2017;177(7):1052-1053. doi:10.1001/jamainternmed.2017.1783